Guilherme Nader Marta (@GuiNaderMarta) ranks #23 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 5 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: TROPION-Breast02. CMS Open Payments lists $60 in 2025 general payments.
At a Glance
- 1 posts naming a trial in 2026
- 1 trials discussed by name
- Breast Cancer: US #23 · 5 physicians engaged
- Presented at ASCO 2026 in 2026
- CMS Open Payments lists $60 in 2025 general payments.
This Month
What Guilherme Nader Marta has posted in the last 30 days. Updated November 10, 2026.
Important data presented at #ESMO2026 TROPION-Breast02 | 1L mTNBC with brain metastases • Median CNS PFS: 9.5 vs 2.6 months (HR 0.27) • Intracranial ORR: 62.5% vs 37.5% Dato-DXd showed great activity, regardless of prior CNS-directed therapy in TNBC @OncoAlert https://t.co/M84knqaYE0
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies Guilherme Nader Marta
Physicians who reposted Guilherme Nader Marta’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #23 | — | 5 | 5 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Guilherme Nader Marta presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ASCO 2026 · Poster (#138)Organ- and histology-specific molecular and immune landscape of metastatic breast cancerSource: @DFCI_BreastOnc on X ↗
Trials Guilherme Nader Marta Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| TROPION-Breast02 | 1 | #8 of 26 | Oct 24, 2026 |
Guilherme Nader Marta on TROPION-Breast02
Important data presented at #ESMO2026 TROPION-Breast02 | 1L mTNBC with brain metastases • Median CNS PFS: 9.5 vs 2.6 months (HR 0.27) • Intracranial ORR: 62.5% vs 37.5% Dato-DXd showed great activity, regardless of prior CNS-directed therapy in TNBC @OncoAlert https://t.co/M84knqaYE0
Guilherme Nader Marta’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
FourLight-1 presented by @antgiorda at #ESMO26 Atirmociclib + fulvestrant improved median PFS vs investigator’s choice after CDK4/6i progression in HR+/HER2− metastatic breast cancer (9.4 vs 6.6 months; HR 0.60; p=0.0007) @DFCI_BreastOnc @OncoAlert https://t.co/Izo75JxXQx
Very interesting data from PREDICT-HER Baseline ¹⁸F-HER2 PET may help identify pts unlikely to respond to T-DXd • NPV for response: 88% (100% in HER2-low/zero) • Median PFS: 5.1m with HER2-PET–negative vs 13.6m with HER2-PET–positive disease @OncoAlert #ESMO2026 https://t.co/a5OpC6A2w9
Industry Payments
CMS Open Payments · 2025 general payments
$60 across 1 payments